Vir Biotechnology, Inc. Tenant Improvements
Vir Biotechnology, Inc. (VIR) had Tenant Improvements of $10.50 million as of 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Balance Sheet › Assets
us-gaap:TenantImprovements · last filed 2021-02-25
- 2020-12-31: Tenant Improvements $10.50M.
| Period end | Tenant Improvements |
|---|---|
| 2020-12-31 | $10.50M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |